Navigation Links
Southern Research Names Mark Suto Vice President of Drug Discovery
Date:8/12/2011

BIRMINGHAM, Ala., Aug. 12, 2011 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that pharmaceutical executive Mark J. Suto, Ph.D., has been named Vice President of the Drug Discovery Division. Dr. Suto and his team will focus on basic research and target identification and lead discovery and optimization of new therapies for cancer, infectious diseases and neurological diseases and disorders.

(Photo: http://photos.prnewswire.com/prnh/20110812/DC51455)

"Mark Suto has demonstrated outstanding scientific and management skills in his career, and adds tremendous strength to our Drug Discovery program," said Jack Secrist, President and CEO. "He will bring new energy to Southern Research at a time when our clients need help in expanding their drug candidate pipelines, and when we are investing internal research dollars into developing our own proprietary technologies."

Dr. Suto comes to Southern Research from Icagen Inc., where he served as Vice President of Chemical and Pharmaceutical Sciences since April, 2004.  From 2003 until 2004, Dr. Suto was Executive Vice President and Chief Scientific Officer of Neurion Pharmaceuticals, Inc., a California biotech company and from 1999 to 2002, Dr. Suto held senior management roles at DuPont Pharmaceuticals (acquired by Bristol-Myers Squibb Company) and Deltagen Research Laboratories, a subsidiary of Deltagen, Inc.  

Prior to DuPont Pharmaceuticals, Dr. Suto held management positions at CombiChem, Inc. and Signal Pharmaceuticals, Inc. and from 1982-1993, held positions of increasing responsibility in the Chemistry Department at Parke-Davis Pharmaceutical Research in Ann Arbor, Michigan. Dr. Suto received his Ph.D. and his Bachelor's degree in Medicinal Chemistry from the State University of New York at Buffalo.

He is a member of the American Chemical Society and has served on the Editorial Boards for several scientific journals, including Combinatorial Chemistry and High Throughput Screening, Investigational Drugs Section Editor, Expert Opinion in Drug Discovery, and Expert Opinion on Therapeutic Patents.  He currently holds 35 U.S. Patents, and has five additional U.S. Patents pending.

ABOUT SOUTHERN RESEARCH

Southern Research Institute is a not-for-profit 501(c)(3) scientific research organization founded in 1941 that conducts preclincal drug discovery and development, advanced engineering research in materials, systems development, and environment and energy research. More than 550 scientific and engineering team members support clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental and energy industries. Southern Research is headquartered in Birmingham, Ala., with facilities in Wilsonville, Ala., Frederick, Md., and Durham, NC and offices in Huntsville, Ala., New Orleans, La., Washington, DC and Kiev, Ukraine.  

CONTACT: Rhonda Jung
Jung@SouthernResearch.org
205-337-9634


'/>"/>
SOURCE Southern Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HASCO Medical Inc. Names Mike Dumais the Vice President of Sales for Southern Medical and Mobility
2. A New Audio Interview With Jerry Overcash, Director for Southern Home Medical Equipment, Inc., is now at SmallCapVoice.com
3. Southern Home Medical Equipment Reports Significant Growth from Encore Franchisees
4. Southern Home Medical Equipment Reports First Quarter 2011 Results in Revenues and Profits
5. Southern Home Medical Equipment Launches Respi-Care Respiratory Therapy Program
6. Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010
7. Southern Research Scientists to Present New Data at the American Association for Cancer Research 102nd Annual Meeting in Orlando
8. Southern Home Medical Equipment Appoints Jerry Overcash to the Board of Directors
9. Southern Home Medical Equipment Engages Northern Virginia Based Waterford Holdings Group to Evaluate and Consider Acquisition Candidates in the Mid-Atlantic Area
10. Encinitas Nursing and Rehabilitation Center First in Southern California to Deploy Voice Technology for Outcomes-Based Care
11. MinuteClinic and St. Rose Dominican Hospitals Form Clinical Collaboration to Improve Access to Health Care in Southern Nevada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... , media relations, content marketing, social media management, corporate communications, SEO and cause ... the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus ...
(Date:2/23/2017)... Colorado (PRWEB) , ... February 23, 2017 , ... ... Magazine, an exciting, new, interactive publication where generations converge and explore the world ... expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):